ClinicalTrials.gg

Program

lifileucel

Also written as “LN-145”, “Lifileucel” and “Autologous Tumor Infiltrating Lymphocytes”.

Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Liposarcoma · Uterine Cervical Neoplasms · Endometrial Neoplasms, led by 2 companies.

Furthest: phase 3, since Feb 6, 202312 company-led studies, 7 open or runningNext primary completion: Jan 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Iovance Biotherapeutics105 open or runningphase 3since Feb 6, 2023Feb 3, 2015Dec 2027phase 2 · NCT07288203
Shanghai Juncell Therapeutics22 open or runningphase 2since Apr 24, 2026Jun 18, 2024Jan 1, 2027phase 1 · NCT06473961

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 3, 2015First study: phase 2 study in MelanomaNew to Iovance BiotherapeuticsIovance Biotherapeutics · NCT02360579 · 220 enrolled · United States, France, Germany and more
  2. Mar 14, 20172 phase 2 studiesIovance Biotherapeutics · NCT03083873, NCT03108495
  3. Jan 14, 2018Phase 2 study in Carcinoma, Non-Small-Cell LungIovance Biotherapeutics · NCT03419559 · United States
  4. Aug 22, 2018Phase 2 study in MelanomaIovance Biotherapeutics · NCT03645928 · 225 enrolled · United States, Canada, Germany and more
  5. Oct 21, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungIovance Biotherapeutics · NCT04614103 · 170 planned · United States, Australia, Canada and more
  6. Feb 6, 2023Phase 3 study in MelanomaIovance Biotherapeutics · NCT05727904 · 670 planned · United States, Australia, Belgium and more
  7. Jun 18, 2024Shanghai Juncell Therapeutics's first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Shanghai Juncell TherapeuticsShanghai Juncell Therapeutics · NCT06473961 · 20 planned · China
  8. Jun 25, 2024Phase 2 study in Endometrial NeoplasmsIovance Biotherapeutics · NCT06481592 · 60 planned · United States
  9. Dec 9, 2025Phase 2 study in MelanomaIovance Biotherapeutics · NCT07288203 · 24 enrolled · United States, Australia, Canada and more
  10. Apr 24, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedShanghai Juncell Therapeutics · NCT07560111 · 28 planned · China
  11. Jul 28, 2026Phase 2 study in SarcomaIovance Biotherapeutics · NCT07741877 · 80 planned · United States

Ahead

  1. Jan 1, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungShanghai Juncell Therapeutics · NCT06473961
  2. Jun 1, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungShanghai Juncell Therapeutics · NCT07560111
  3. Dec 2027Primary completion: phase 2 study in MelanomaIovance Biotherapeutics · NCT07288203
  4. Mar 1, 2028Primary completion: phase 3 study in MelanomaIovance Biotherapeutics · NCT05727904

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07741877Sarcoma · United States2RecruitingIovance BiotherapeuticsSep 1, 203380
NCT07560111Carcinoma, Non-Small-Cell Lung · China2RecruitingShanghai Juncell TherapeuticsJun 1, 202728
NCT07288203Melanoma · United States, Australia, Canada and more2Active, not recruitingIovance BiotherapeuticsDec 202724
NCT06481592Endometrial Neoplasms · United States2RecruitingIovance BiotherapeuticsMay 202860
NCT06473961Carcinoma, Non-Small-Cell Lung · China1RecruitingShanghai Juncell TherapeuticsJan 1, 202720
NCT05727904Melanoma · United States, Australia, Belgium and more3RecruitingIovance BiotherapeuticsMar 1, 2028670
NCT04614103Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2RecruitingIovance BiotherapeuticsDec 2030170
NCT03645928Melanoma · United States, Canada, Germany and more2TerminatedIovance BiotherapeuticsFeb 20, 2026225
NCT03419559Carcinoma, Non-Small-Cell Lung · United States2WithdrawnIovance BiotherapeuticsDec 20210
NCT03108495Uterine Cervical Neoplasms · United States, France, Germany and more2TerminatedIovance BiotherapeuticsAug 22, 2025210
NCT03083873Squamous Cell Carcinoma of Head and Neck · United States2CompletedIovance BiotherapeuticsAug 8, 202264
NCT02360579Melanoma · United States, France, Germany and more2CompletedIovance BiotherapeuticsOct 24, 2024220

How it is read

Names in the registry

  • “LN-145”, 6 entries
  • “Lifileucel”, 5 entries
  • “Autologous Tumor Infiltrating Lymphocytes”, 2 entries
  • “LN-145 + pembrolizumab”, 1 entry
  • “Lifileucel plus Pembrolizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.